New ultrasound technique could spot placental problems early

NCT ID NCT02884297

Completed Knowledge-focused Sponsor: Centre Hospitalier Régional Metz-Thionville Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested whether a special ultrasound with a contrast agent (SonoVue®) can measure blood flow in the placenta during the first three months of pregnancy. Fifty-five women who had already decided to end their pregnancy took part. The goal was to see if this method works better than standard ultrasound for checking placental health.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SonoVue® (sulfur hexafluoride contrast agent)
What this could lead to: If successful, this could lead to a new way to measure placental blood flow early in pregnancy, potentially helping to detect problems like preeclampsia or growth restriction.
What could go wrong: This is a small feasibility study in women already scheduled for termination, so results may not apply to ongoing pregnancies. The contrast agent also carries rare risks like allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREGNANCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PREGNANCY

Contacts and locations

Locations

CHRU de NANCY

Nancy, 54511, France
Chr Metz Thionville

Metz, 57085, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.